You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer

  • Technology appraisal guidance
  • Reference number: TA531
  • Published:  18 July 2018
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final appraisal determination
  3. Invitation to participate

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 222 KB)

    Published:
    18 July 2018
  • Committee papers TA477 ACD committee papers (PDF 3.16 MB)

    Published:
    18 July 2018
  • Committee papers TA447 FAD committee papers (PDF 12.89 MB)

    Published:
    18 July 2018

Final appraisal determination

  • Final appraisal determination

  • Final appraisal determination document (PDF 373 KB)

    Published:
    06 June 2018
  • Committee papers (PDF 15.49 MB)

    Published:
    06 June 2018
  • Public committee slides (PDF 908 KB)

    Published:
    06 June 2018

Invitation to participate

  • Final scope (PDF 254 KB)

    Published:
    31 October 2017
  • Final matrix (PDF 261 KB)

    Published:
    31 October 2017
Back to top